Diabetes is a medical condition that is now recognized as a major chronic pandemic disease globally. It is caused due to insufficient production and secretion of insulin from the pancreas in the case of Type-I Diabetes and defective response of insulin Type-2 diabetes.
Around 143 million people globally are affected by Diabetes, and in India, about 5 percent of the population suffers from it. The complications of Diabetes are a major cause of morbidity and mortality in India. As per WHO, 80 percent of mortality due to Diabetes occurs in low and middle-income countries. In India, the rate of diabetic patients can increase to 58%, from 51 million people in 2010 to 87 million in 2030. Currently, with already more than 50 million patients India is already considered the Diabetic capital of the world, and it’s high time for assessment of the economic burden of the disease. The Government of India launched the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) in 2010. As of March 2017, the data obtained by this program only covered half the population with discreet results. The poor planning and weak implementation of the program left out the blind spots, due to which a large chunk of the patients cannot access affordable treatment. Diabetes can be curbed at the initial level by introducing lifestyle changes and controlled after its incidence through medicines in the early stages and administration of external insulin in advanced stages. It would be too irrational to say that Diabetes is there for a long stay and cannot be ridden in a lifetime. Multiple studies have advocated the need for a comprehensive campaign regarding Diabetes and associated risk factors to minimize the burden of Diabetes. The medical fraternity strongly asserts that regular check-ups and timely detection play a vital role in controlling and managing the risk of chronic stress. The main irony in managing the disease is the mentality and the resistance shrouding the patients with a certain feeling of disbelief that ‘I can have diabetes too.’ Hence, a bulk of the patient profile usually delays early detection and treatment, which ultimately leads to complications. With the government’s huge repository of data and new initiatives, there has been a mandate for bringing the entire gambit of chronic patients under an effective treatment management plan. The newer treatment guidelines advocate that altering the lifestyle and diet habits compounded with increasing the quantity and quality of physical activity can help one achieve the targeted glycemia in patients with type 2 diabetes mellitus. Both structured and unstructured training has been found to provide benefits, but the structured regime has been more effective in reducing the Hb1Ac levels significantly.
J Mitra & Co. also understands the gravity of the situation and is committed to addressing the disease’s economic burden and has been at the forefront by providing affordable and reliable diagnostic kits for timely intervention and proper diagnosis. The Hb1Ac kit developed by J Mitra is a world-class product in its own right and has been approved by NGSP. The kit’s efficacy is evident in the fact that it has been accepted widely by customers all across the country. For this Hb1Ac kit to be used, J Mitra has introduced the fluorescent immunoassay technique catered by the indigenously developed analyzer, iQuant.
